We further tested whether treatment without or with a readthrough enhancer could reverse aberrant lysosomal phenotypes previously described in several preclinical models of FTLD-GRN as well as neuronal ceroid lipofuscinosis (NCL) due to progranulin deficiency [15–17]. The gene discussed is GRN; the disease is hyperinsulinemic hypoglycemia, familial, 4.